Proteomic and metabolomic characterization of bone, liver, and lung metastases in plasma of breast cancer patients.

Hui YeXiabo ShenYaohan LiWeibin ZouSyed Shams Ul HassanYue FengXiaojia WangJingkui TianXiying ShaoYi TaoWei Zhu

Published in: Proteomics. Clinical applications (2024)

For bone metastasis, biomarkers such as leucyl-tryptophan, LysoPC(P-16:0/0:0), FN1, and HSPG2 have been validated. dUDP, LPE(18:1/0:0), and aspartylphenylalanine have been confirmed for liver metastasis. For lung metastasis, dUDP, testosterone sulfate, and PE(14:0/20:5) have been established.

Keyphrases

bone mineral density
soft tissue
bone loss
bone regeneration
postmenopausal women
replacement therapy
label free